Exact Mass: 365.0722
Exact Mass Matches: 365.0722
Found 34 metabolites which its exact mass value is equals to given mass value 365.0722,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
p38 MAP Kinase Inhibitor
3-(1,3-benzothiazol-2-yl)-6-ethyl-4-oxo-4H-chromen-7-yl acetate
tert-Butyl 4-(4-bromo-2-cyanophenyl)piperazine-1-carboxylate
S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth
L-Cysteine,N-[(4-methylphenyl)sulfonyl]-S-(phenylmethyl)-
Itazigrel
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent C471 - Enzyme Inhibitor
Adenosine 5-monophosphate monohydrate
Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2.
2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide
8-Carboxy-2,4,6,9-tetrahydroxy-7-methyltetracen-5-olate
[(1S)-2-[2-[(2R)-2-amino-2-carboxyethyl]selanyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium
tetracenomycin F1(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.
2-(2-bromo-4-tert-butylphenoxy)-N-(2-furanylmethyl)acetamide
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
N-[5-fluoro-2-(3-oxo-4H-quinoxalin-2-yl)phenyl]-2-thiophenecarboxamide
4-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide
5-(3,4-Dimethoxyphenyl)-2-phenyl-4-thieno[2,3-d][1,3]oxazinone
1-[(E)-[3-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methylideneamino]-3-ethylthiourea
2-(4-Bromo-3-methylphenyl)-4-[(3-methoxypropylamino)methylidene]-5-methyl-3-pyrazolone
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
1-(2-Furanylmethyl)-4-[oxo(thiophen-2-yl)methyl]-5-phenylpyrrolidine-2,3-dione
Afizagabar
Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy[1].
GYKI 52466 (dihydrochloride)
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research[1][2].
